Abramson, John

faculty, Harvard Medical School; family physician; former pharmaceutical litigation expert witness; author of Sickening: How Big Pharma Broke American Health Care and How We Can Fix It

John Abramson: Big Pharma

Lex Fridman Podcast · Feb 11, 2022

• John Abramson
• Sickening (book)
• pharmaceutical industry litigation
• Vioxx and data manipulation
• Trulicity and drug advertising
• peer review transparency
• FDA-industry revolving door
• Aduhelm approval controversy
• COVID vaccine data transparency
• health care spending vs. outcomes

Core ideas

Abramson argues the single most impactful fix to American health care would be restoring the independence of the medical knowledge doctors rely on — clinical trial publications, peer review, and practice guidelines — which he says has been captured by pharmaceutical industry commercial interests optimized for shareholder returns rather than patient health. He frames this using a sports analogy: capitalism can work in medicine, but only with strong independent "referees," which he says the U.S. largely lacks compared to other wealthy nations. Drawing on roughly a decade as an expert witness in pharmaceutical litigation (including the case that produced, he says, the largest criminal fine in U.S. history at the time and a 2010 jury verdict finding Pfizer guilty of fraud and racketeering), he argues drug companies routinely violate marketing and data-disclosure law, paying an estimated $38 billion in fines from 1991–2017 without individual executives facing prison — fines he says are typically smaller than the profits earned from the underlying violations, making them a cost of doing business rather than a genuine deterrent.

Rather than attributing this to individual malevolence, Abramson argues it reflects a captured corporate "cultural milieu" in which normal, well-intentioned employees gradually internalize profit-maximization as the ethical baseline, since career survival and advancement within the company depend on it — comparing this to his own observation that people become reluctant to criticize others who fund them, even without consciously deciding to be dishonest. He illustrates this with the case of Vioxx (withdrawn from market in 2004 after a company-sponsored study showed it more than doubled cardiovascular risk): a 2000 New England Journal of Medicine study on the drug, he says, omitted three heart attacks from its published cardiovascular data — known to Merck employees among the paper's authors and to the FDA — with the researcher overseeing the trial's safety-monitoring cutoff signing a paid consulting contract with Merck shortly after a decision was made to stop counting cardiovascular events early. He similarly discusses Trulicity, a diabetes drug costing roughly $6,200/year (versus ~$4/month for metformin), whose advertising highlights a statistically significant cardiovascular benefit without disclosing that 323 people must be treated to prevent one non-fatal event, or that an NIH-funded study (the Diabetes Prevention Program) found intensive lifestyle intervention outperformed metformin at preventing diabetes — evidence he says is systematically absent from advertising and, he argues, from the incentive structure of industry-funded research generally, since drug companies fund studies designed to prove a drug is better than nothing rather than better than lifestyle change.

Abramson argues the peer-review system that doctors are trained to trust does not actually verify underlying clinical trial data — peer reviewers see only the submitted manuscript, not the raw data — and proposes reforms including independent, adequately incentivized statisticians reviewing full clinical study reports before publication, and eventually broader public/citizen-scientist access to trial data. On the FDA specifically, he discusses the agency's multi-year timeline (and Pfizer's court filing supporting the FDA's position) for releasing COVID-19 vaccine trial data under a Freedom of Information Act request, stating he suspects — while explicitly identifying as pro-vaccine and stating current real-world data show vaccination reduces COVID mortality risk roughly 20-fold — that something in the withheld data may prove embarrassing to the FDA or Pfizer, drawing a parallel to a separate case where the FDA overruled its own advisory committee's unanimous 10-0 vote against approving the Alzheimer's drug Aduhelm, after which the FDA's drug-review chief (a former pharmaceutical industry executive) suggested loosening conflict-of-interest rules for advisory panels. He argues on principle for a ban on individuals moving between pharmaceutical companies and regulatory agencies, and separately criticizes the law barring Medicare from negotiating drug prices directly, tracing it to a 2003 provision whose chief legislative sponsor took a lobbying job in the pharmaceutical industry shortly after leaving Congress.

Discussing the pandemic response, Abramson credits Operation Warp Speed and NIH-funded mRNA infrastructure research for the vaccines' rapid development, but criticizes the U.S. government for not requiring recipients of guaranteed vaccine contracts to participate in global distribution, noting roughly 85% of early doses went to wealthy nations while a 2021 request from the WHO/WTO/IMF/World Bank for $50 billion to fund developing-world vaccination went largely unmet — an amount he notes was less than the roughly $50 billion in personal wealth gained by a small number of vaccine-linked billionaires in the same period — arguing this reflects a genuine self-interest failure (since unvaccinated global populations breed new variants that return to harm Americans), not merely an ethical one. On censorship and scientific discourse, Abramson states he doesn't believe "everyone is allowed their own scientific facts," but is broadly skeptical that top-down censorship of contested claims (e.g., around vaccine skepticism) is more effective than requiring scientists to be better public communicators and pushing for stronger pre-publication transparency and real-time, independent fact-checking of contested claims, framing distrust of institutions as a predictable response to genuinely compromised institutional independence rather than pure misinformation. On overtreatment, Abramson discusses antidepressants, citing research (attributed to Eric Turner) that they show meaningful benefit primarily for major depression, not the broader range of common sadness and dissatisfaction they are frequently prescribed for, and argues this reflects a cultural "medicalization" of ordinary suffering that discourages diagnosing and addressing its actual social, relational, or economic causes.

More broadly, Abramson argues the U.S. spends roughly 7 percentage points more of GDP on health care than comparable wealthy nations while ranking far lower in health outcomes (he cites a fall from 38th to 68th in healthy life expectancy since 2000 despite roughly $1.5 trillion in excess annual spending), attributing this to a systemic overinvestment in profitable drug/device development (96% of U.S. clinical research funding, by his account) relative to preventive, lifestyle, and social-determinants-of-health approaches — a ratio he says is inverted relative to healthier, lower-spending peer nations. He argues NIH leadership (naming Francis Collins and Anthony Fauci) bears responsibility for not more forcefully elevating preventive and lifestyle health messaging alongside drug development. He closes with practical health advice (regular exercise, not smoking, maintaining healthy weight, while acknowledging socioeconomic constraints on these choices), reflections on a personal near-death experience he says left him feeling liberated from anxiety about mortality, and a view that a meaningful life consists of committing wholeheartedly to something one cares about, provided it doesn't harm others.

Excerpts